← Back to Search

Virus Therapy

COVID-19 Vaccine for Coronavirus Disease (VIC Trial)

N/A

Waitlist Available

Led By Richard J Simpson, PhD

Research Sponsored by Forrest Baker

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

'low risk' for submaximal exercise testing in accordance with the risk stratification guidelines published by the American Heart Association and the American College of Sports Medicine (AHA/ACSM criteria). We will also determine the participant's current vaccine status (influenza, chickenpox, etc) and COVID-19 infection status. Infection status will be determined via self-report and Spike protein IgG titer levels We will simply ask the participant (self-report) when they received the vaccine and, if they know, which vaccine they received (e.g. Moderna or Pfizer for the COVID-19 vaccine). However, only participants that have been vaccinated (1-3 weeks after second dose) or tested positive (greater than 2-months symptom free) for COVID-19 by either PCR, antigen, or antibody testing will be eligible for Aim 2. After providing informed consent, all participants will undergo a comprehensive screening procedure to ensure that AHA/ACSM criteria are met.

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 year

Awards & highlights

VIC Trial Summary

This trial is testing the effects of exercise on anti-viral immunity against many types of common viruses before and after vaccination.

Eligible Conditions

Coronavirus Disease
Influenza

VIC Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

VIC Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Determine IFN-γ concentration after whole blood stimulation with SARS-CoV-2 peptides

Determine IFN-γ spot forming cells after stimulation with SARS-CoV-2 peptides

Determine SARS-CoV-2 T-cell phenotype

+2 more

VIC Trial Design

1Treatment groups

Experimental Treatment

Group I: VaccineExperimental Treatment1 Intervention

Participants who elect to receive the vaccine

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

COVID-19 Vaccine

2021

N/A

~8590

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Forrest BakerLead Sponsor

University of ArizonaLead Sponsor

514 Previous Clinical Trials

148,243 Total Patients Enrolled

Richard J Simpson, PhDPrincipal InvestigatorUniversity of Arizona

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the projected sample size for this clinical experiment?

"Affirmative. Information posted on clinicaltrials.gov reveals that this research project, which was initially unveiled on March 9th 2021, is currently recruiting participants. Approximately 30 persons need to be recruited from 1 medical institution."

Answered by AI

Are opportunities available for individuals to take part in this experiment?

"Affirmative. The clinical trial registry on clinicialtrials.gov indicates that this medical research is currently recruiting patients; the study was first publicized on March 9th 2021 and has been updated most recently on September 28th 2021. 30 volunteers are sought from a single healthcare facility."

Answered by AI

Is eligibility for this medical research limited to individuals aged fifty or below?

"This clinical trial demands that participants must be 18 years or older, with the upper age limit placed at 44."

Answered by AI

What criteria should participants meet in order to be eligible for this clinical trial?

"This clinical trial has a limited number of spots available, specifically 30 people who have respiratory tract infections and are between 18 to 44 years old."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Exercise and COVID-19 Viral T-cell Immunity

Forrest Baker 2021. "Exercise and COVID-19 Viral T-cell Immunity". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05019456.